drugset
Drugs / CS6253
last change Mar 2026 re-read 3 minutes ago

CS6253

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 0 NCT05965414 Comparator Oct 2023 → Jul 2024 Alzheimer disease Artery Therapeutics, Inc. Completed No outcome recorded

Press releases naming this drug 8 releases

DateIssuerRelease
2026-03-19 Artery Therapeutics, Inc. Jan Johansson will deliver an oral presentation on the latest clinical data for CS6253 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) in Copenhagen, Denmark. arterytx.com ↗
2026-03-03 Artery Therapeutics, Inc. Artery has been awarded a NIH–NIA Cooperative Agreement grant, a rigorous highly competitive federal peer-review milestone, to advance CS6253 into clinical trials in Alzheimer’s patients. arterytx.com ↗
2024-04-05 Artery Therapeutics, Inc. Artery is pleased to inform that the Drug Safety and Monitoring Board today concluded that CS6253 was safe and showed favorable pharmacokinetics in the Phase 1 Single Ascending Dose study (n=40), and recommended the transition to the Phase 1 Multiple Ascending Dose Study (NCT05965414). arterytx.com ↗
2021-09-21 Artery Therapeutics, Inc. Artery receives NIH-NIA fast-track SBIR grant to open up IND and perform First in Human testing of the ABCA1 agonist CS6253 indicated for the treatment of hereditary APOE4 associated Alzheimer’s disease. arterytx.com ↗
2020-11-04 Artery Therapeutics, Inc. Artery is presenting a poster and short video at CTAD 2020, titled "CS6253 ABCA1 agonist treatment in cynomolgus monkeys reduces cerebrospinal fluid concentrations of Aβ42, Aβ40, APP and AP2B1 in dose-response manner." The authors are J.O. arterytx.com ↗
2019-06-01 Artery Therapeutics, Inc. Artery Therapeutics, Inc (Artery) is pleased to announce that the National Institute of Aging (NIA) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) fast-track grant to advance "CS6253 for the treatment of apoE4-driven dementia including Alzheimer’s disease". arterytx.com ↗
2019-03-27 Artery Therapeutics, Inc. Exciting new CS6253 data will be presented at AD/PD 2019 meeting in Lisbon, Portugal. arterytx.com ↗
2018-11-03 Artery Therapeutics, Inc. Artery is pleased to announce that three abstracts containing new CS6253 data will be presented at Society for Neuroscience annual meeting (SfN2018) in San Diego. arterytx.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CS6253 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05965414 ↗
Route Intravenous “a single IV bolus injection (CS6253 1, 2.4, 6, and 10 mg/kg or placebo) will be administered” NCT05965414 ↗